Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation

NCT02448797 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

320

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Icotinib
DRUG: Chemotherapy

Sponsor

Betta Pharmaceuticals Co., Ltd.